The legal action, initiated by Levi & Korsinsky, LLP, centers on allegations that Erasca misled shareholders regarding its ERAS-0015 drug candidate. Throughout the class period, the company repeatedly compared the drug to Revolution Medicines’ RMC-6236, claiming superior binding affinity and efficacy at significantly lower doses. These assertions allegedly concealed critical intellectual property risks and the limitations of comparing the drugs without head-to-head clinical data.
In section Releases
Investors Face August Deadline in Erasca Securities Class Action
Investors who purchased Erasca, Inc. securities between January 14, 2025, and April 26, 2026, face an August 10, 2026, deadline to seek lead plaintiff status. The class action follows a 53.9% collapse in share price triggered by disclosures of patent litigation and a fatal incident in clinical trials.
Market confidence evaporated on April 27, 2026, when the company issued two corrective disclosures. The first revealed a patent infringement and trade secret misappropriation letter from RevMed. The second, released after market hours, disclosed a Grade 5 patient death in Phase 1 trials and acknowledged that previous performance comparisons lacked scientific validity. The stock price dropped from $21.49 to $9.90, wiping out over half of its value in a single day. Investors who suffered losses during this period are encouraged to contact the firm to review their eligibility for recovery, as the lawsuit proceeds on a contingency basis with no upfront costs for participants.
Comments (0)
No comments yet. Be the first!